妊娠合并艾森门格综合征靶向药物治疗成功:病例系列与文献综述
该回顾性病例系列纳入2011至2021年间在中南大学湘雅二医院分娩的13例艾森门格综合征孕妇,其中12例(92%)接受靶向药物治疗,无孕产妇死亡,但9例(69%)发生心力衰竭,12例(92%)早产,10例(77%)分娩活婴,活婴中9例(90%)为低出生体重儿。文献综述汇总11项研究共72例妊娠合并艾森门格综合征病例,靶向药物使用率低(28%),围产期孕产妇死亡率为24%。作者认为靶向药物可能是改善艾森门格综合征孕产妇死亡率的关键。
要点
- 13例艾森门格综合征孕妇中12例(92%)接受靶向药物治疗,无孕产妇死亡。
- 9例(69%)发生心力衰竭,12例(92%)早产,10例(77%)分娩活婴。
- 文献综述72例中靶向药物使用率28%,围产期孕产妇死亡率24%。
核心结论
- 本病例系列和文献综述提示,靶向药物可能是改善艾森门格综合征孕产妇死亡率的关键。
研究设计与样本
- 回顾性病例系列与文献综述。
- 研究机构为中南大学湘雅二医院(三级转诊医院)。
- 样本为2011年至2021年间分娩的13例艾森门格综合征孕妇。
主要发现
- 13例孕妇中12例(92%)接受靶向药物治疗。
- 9例(69%)发生心力衰竭,无孕产妇死亡。
- 12例(92%)选择剖宫产分娩;1例于37+1周分娩,其余12例(92%)为早产。
- 10例(77%)分娩活婴,其中9例(90%)为低出生体重儿,平均出生体重1575 g;婴儿死亡率为1/10(10%)。
- 入院时11例(85%)孕妇心功能III/IV级,出院时12例(92%)为II/III级。
临床怎么用
- 作者认为靶向药物可能是改善艾森门格综合征孕产妇死亡率的关键。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To clarify the real-world outcomes in pregnant women with Eisenmenger syndrome (ES) in the new therapeutic era and provide a literature review. DESIGN: Retrospective case and literature review. SETTING: Tertiary referral hospital (The Second Xiangya Hospital of Central South University). SAMPLE: Thirteen women with ES delivered between 2011 and 2021. METHODS: Respective study and literature reviews. MAIN OUTCOMES MEASURES: Maternal and neonatal mortality and morbidity. RESULTS: 12/13 (92%) pregnant women were treated with targeted drugs. 9/13 (69%) of patients had heart failure, but no maternal deaths occurred. 12/13 (92%) of women chose caesarean delivery. One pregnant woman gave birth at 37+1 weeks, and the remaining 12 (92%) patients had preterm birth. 10/13 (77%) women gave birth to live infants, of which 9/10 (90%) were low birthweight infants with a mean birthweight of 1575 g. The infant mortality rate was 1/10 (10%). Cardiac functional class improved during pregnancy, probably due to therapy; 11/13 (85%) of the pregnant women were in cardiac functional level III/IV at admission and 12 (92%) were in cardiac functional class II/III at discharge. Our literature review identified 72 cases of pregnancy with ES from 11 studies, which were characterised by a low rate of targeted drug use (28%) and a high maternal mortality rate of 24% in the perinatal period. CONCLUSION: Our case series and literature review suggest that targeted drugs may be key to improving maternal mortality in ES.
引用
- Chen W, Chen J, Peng M, et al. Successful Eisenmenger syndrome-targeted drug therapy in pregnant women: a case series and literature review. BJOG. 2023. PMID: 36802098. doi:10.1111/1471-0528.17427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。